

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


GP RECEIVED  
PATENT APPLICATION

Inventor(s): CHANDRASEGARAN  
 Appln. No.: 09 | 281,792  
 Series Code ↑ | Serial No. ↑

Filed: March 31, 1999

Hon. Commissioner of Patents  
 Washington, D.C. 20231

Sir:

**REPLY/AMENDMENT/LETTER**

Group Art Unit: 1648  
 Examiner: H.T. Park  
 Atty. Dkt. PM 259804 | C-1288

Appln. Title: METHODS FOR INACTIVATING  
 TARGET DNA AND FOR DETECTING  
 CONFORMATIONAL CHANGE IN A  
 NUCLEIC ACID

Date: November 15, 2000

#4

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED**

1. Small Entity claim		Claims remaining after amendment		Highest number previously paid for		Present Extra		Large/Small Entity		Additional Fee		Fee Code Lg/Sm	
A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input checked="" type="checkbox"/> made previously													
For B & C See Required Separate Paper (Pat-256)													
2. Total Effective Claims		8		**minus 20		0		x \$18/\$9 =		+ \$0		103/203	
3. Independent Claims		1		***minus 3		0		x \$80/\$40 =		+ \$0		102/202	
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) .....								+ \$260/\$130 =		+ \$0		104/204	
5. Original due Date: November 15, 2000		<input type="checkbox"/> NONE											
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)		\$110/\$55 =								115/215	
		(2 mos)		\$390/\$195 =		+ \$0						116/216	
		(3 mos)		\$890/\$445 =								117/217	
		(Usable only for ≤ 2mo.OA --- 4 mos)		\$1390/\$695=								118/218	
		(Usable only for 30 day/1mo.OA --- 5 mos)		\$1890/\$945=								128/228	
7. Enter any previous extension fee paid since above original due date and subtract								- \$0					
8. Extension Fee Attached								+ \$0					
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....								+ \$110/\$55		+ \$55		148/248	
10. If IDS attached requires Official Fee under Rule 97 (c), .....								+ \$180		+ \$0		126	
or if Rule 97(d) Request .....								+ \$180				126	
11. After-Final Request Fee per rules 129(a) and 17(r) .....								+ \$710/355		+ \$0		146/246	
12. No. of additional inventions for examination per Rule 129(b) .....								x \$710/355 ea		+ \$0		149/249	
13. Request for Continued Examination (RCE) .....								+ \$710/355		+ \$0		1179/1279	
14. Petition fee for .....										+ \$0			
15. TOTAL FEE ENCLOSED =												\$55	

15.

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 41060 | 259804  
 C# | M#)

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP  
 Intellectual Property Group

By Atty: Ann S. Hobbs

Reg. No. 36830

1100 New York Avenue, NW  
 Ninth Floor  
 Washington, DC 20005-3918  
 Tel: (202) 861-3000  
 Atty/Sec: ASH/JRH

Sig:

Fax: (202) 822-0944  
 Tel: (202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

RECEIVED

NOV 20 2000

TECH CENTER 1600/2900


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CHANDRASEGARAN

Appln. No.: 09/281,792

Filed: March 31, 1999



Group Art Unit: 1648

Examiner: H. T. Park

#4  
11/21/00  
H. T. Park

FOR: METHODS FOR INACTIVATING TARGET DNA AND FOR DETECTING  
CONFORMATIONAL CHANGE IN A NUCLEIC ACID

\* \* \* \* \*

November 15, 2000

AMENDMENT

Hon. Commissioner of Patents  
Washington, DC 20231

Sir:

In response to the Office Action issued August 15, 2000, please amend the application as follows, enter the Terminal Disclaimer filed herewith and consider the remarks below.

IN THE SPECIFICATION:

Please substitute the attached Sequence Listing for that which was originally filed.

REMARKS

Claims 1-8 are pending. Reconsideration is requested.

Claims 1-8 have been rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-32 of U.S. Pat. No. 5,792,640. Filed herewith is a Terminal Disclaimer over the '640 patent, thereby overcoming the rejection.

The Office Action also included a Notice to Comply with Sequence Listing Requirements. The computer readable form in this application, 09/281,792, is identical with that filed in application no. 08/575,361, filed May 7, 1996. Please use the only computer